SilverHawk 斑块切除系统在股浅动脉支架内再狭窄中的应用

摘要

目的评价 SilverHawk 斑块切除系统在股浅动脉硬化性闭塞症支架内再狭窄治疗中的安全性及近期疗效。方法2011年4月~2012年2月采用 SilverHawk 斑块切除系统治疗下肢动脉硬化闭塞症支架置入术后支架内再狭窄患者共5例（5条肢体）。Rutherford 分级3~5级；TASC Ⅱ分型：A 型3例、B 型1例、C 型1例。除临床症状外，还采用彩超或 CT 血管造影方法对管腔通畅情况进行评估随访。结果本组5例手术均成功，无死亡病例。患者术后症状均较术前减轻，踝肱指数由术前的0.38±0.09上升至0.81±0.09。5例患者获得随访，随访时间8~17[平均(11.4±3.1)]个月；1例在术后6个月时出现再狭窄，行左大腿截肢术；余4例患者随访期内患肢股浅动脉支架内血流通畅。结论SilverHawk 斑块切除系统在股浅动脉支架内再狭窄的治疗中安全有效，近期效果满意。%Objective To evaluate the safety and efficacy of SilverHawk atherectomy device in the treatment of the in-stent restenosis in the superficial femoral artery(SFA) . Methods From Apr. 2011 to Feb. 2012,5 patients with in-stent restenosis (Rutherford score of 3~5,TASC Ⅱ classification:TASC A in 3 cases, TASC B in l case ,TASC C in 1 Case) were treated by SilverHawk atherectomy devices. All the patients were diagnosed via low-extremity artery CTA or Doppler ultrasonography. Results The overall technical success rate was 100 % (5/ 5),with no death. All of the symptoms were relieved. The ABI increased from 0.38±0.09 to 0.81±0.09. All the patients were followed up for 8~17 (mean, 11.4±3.1) months. One patient received leg amputation 6 months after surgery because of restenosis. The patency rate of SFA in the other 5 patients was high. Conclusion It is safe and effective to treat in-stent restenosis of SFA using SilverHawk atherectomy device .The early results were satisfied.